BioSpace News Archive

Abeona did not specify the type of misconduct that Carsten Thiel engaged in, but it was serious enough to warrant termination.

Steven Fang, executive director of Invitrocue with offices in Australia, China and Singapore, took time to talk to BioSpace about the company and the Asian market for biopharma.

Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers. So let’s hear it! Are you happy with your current job?

On June 18-20, 2019, the InnoPack China 2019 hosted by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and UBM EMEA and co-sponsored by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. (UBM Sinoexpo) will present an industrial event integrated with “product display”, “innovation activities”, and “high-end summits” to researchers and purchasers of the pharmaceutical industry in Hall N5 of Shanghai New International Expo Centre in Pudong.

Ireland Strategic Investment Fund and leading global investors back significant expansion of Genomics Medicine Ireland (GMI), creating up to 600 high-value jobs over five years

Helicobacter pylori infection is a major public health issue affecting 60% of the world’s population with 90% of Peptic Ulcers attributed to and 80% of Gastric Cancers associated with Hp infection.

First clinical study of a rationally-defined bacterial consortium for an immune-mediated disease

The SyMRI NEURO software from SyntheticMR AB and the Philips Ingenia Elition 3.0T MR scanner with the synthetic SyntAc sequence are now jointly marketed in the United States.

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for cancer supportive care.